Literature DB >> 7082756

One-sample multiple testing procedure for phase II clinical trials.

T R Fleming.   

Abstract

Commonly, the central objective of Phase II clinical trials is the assessment of the antitumor 'therapeutic efficacy' of a specific treatment regimen. It is of interest to formulate test procedures which can be employed in these trials to decide whether or not this therapeutic efficacy warrants further investigation. For ethical reasons, these procedures should allow for early termination if initial results are extreme. In this paper, a one-sample multiple testing procedure is proposed which employs the standard single-stage test procedure at the last test, and which both allows for early termination and essentially preserves the size, power and simplicity of the single-stage procedure.

Mesh:

Year:  1982        PMID: 7082756

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  220 in total

Review 1.  Stopping rules for phase II studies.

Authors:  N Stallard; J Whitehead; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

2.  Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Suguru Mizuno; Keisuke Yamamoto; Hiroshi Yagioka; Yoko Yashima; Kazumichi Kawakubo; Hirofumi Kogure; Osamu Togawa; Saburo Matsubara; Yukiko Ito; Naoki Sasahira; Kenji Hirano; Takeshi Tsujino; Nobuo Toda; Minoru Tada; Masao Omata; Kazuhiko Koike
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

3.  Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Authors:  Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

Review 4.  Statistics in clinical trials.

Authors:  Stephanie J Green; Donna K Pauler
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

5.  Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity.

Authors:  Xiudong Lei; Ying Yuan; Guosheng Yin
Journal:  Lifetime Data Anal       Date:  2010-04-03       Impact factor: 1.588

6.  Phase II trial of fenretinide in advanced renal carcinoma.

Authors:  Ulka Vaishampayan; Lance K Heilbrun; Ralph E Parchment; Vikash Jain; James Zwiebel; Ramesh R Boinpally; Patricia LoRusso; Maha Hussain
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

7.  A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Authors:  Mary J Mackenzie; Holger W Hirte; Goss Glenwood; Maroun Jean; Rakesh Goel; Pierre P Major; Wilson H Miller; Lawrence Panasci; Ian A J Lorimer; Gerald Batist; Sarah Matthews; Lynn Douglas; Lesley Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

8.  Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer.

Authors:  Elisabetta Campagnoli; Isabella Garassino; Armando Santoro; Fabio De Vincenzo; Paolo Andrea Zucali; Giovanni Luca Ceresoli; Fabio Romano Lutman; Marco Alloisio; Hector Josè Soto Parra; Raffaele Cavina
Journal:  Invest New Drugs       Date:  2007-06-19       Impact factor: 3.850

9.  Phase II trial of menogaril in metastatic adenocarcinoma of the prostate. A Southwest Oncology Group study.

Authors:  S A Taylor; B A Blumenstein; R L Stephens; E D Crawford; B Pistone; J B Hill
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

10.  Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Authors:  E S Casper; M R Green; D P Kelsen; R T Heelan; T D Brown; C D Flombaum; B Trochanowski; P G Tarassoff
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.